(KURA) Kura Oncology - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.001m USD | Total Return: 80.3% in 12m
Avg Turnover: 10.7M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Interest Coverage Ratio -204.1 is critical
Altman Z'' -6.27 < 1.0 - financial distress zone
Extended 1w Choppy
Tailwinds
No distinct edge detected
Kura Oncology, Inc. is a clinical-stage biopharmaceutical firm based in San Diego, California, focused on developing precision medicines for oncology and cardiometabolic diseases. The company’s portfolio is centered on small molecule inhibitors, specifically targeting the menin-MLL protein interaction which plays a critical role in certain genetically defined cancers.
The company’s lead asset, ziftomenib (KOMZIFTI), is an oral menin inhibitor designed for patients with acute myeloid leukemia. In the biotechnology sector, clinical-stage companies typically rely on venture capital or equity markets to fund extensive R&D and clinical trials before achieving commercial revenue. Kura is also expanding its pipeline with darlifarnib for solid tumors and KO-7246 for metabolic disorders, leveraging a business model based on high-value intellectual property and targeted therapeutic applications.
For a more comprehensive look at the companys financial health and valuation metrics, consider reviewing the latest data on ValueRay.
- FDA approval timeline for KOMZIFTI in relapsed or refractory AML
- Clinical data readouts for ziftomenib in frontline combination therapy
- Expansion of menin inhibitor pipeline into diabetes and cardiometabolic disorders
- Strategic partnerships and potential acquisition interest in the oncology space
- Cash runway and future equity financing to fund late-stage development
| Net Income: -294.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.40 > 0.02 and ΔFCF/TA -20.02 > 1.0 |
| NWC/Revenue: 729.1% < 20% (prev 933.1%; Δ -204.1% < -1%) |
| CFO/TA -0.12 > 3% & CFO -78.0m > Net Income -294.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 6.15 > 1.5 & < 3 |
| Outstanding Shares: last quarter (88.6m) vs 12m ago 1.37% < -2% |
| Gross Margin: 93.70% > 18% (prev 0.99%; Δ 9.27k% > 0.5%) |
| Asset Turnover: 10.26% > 50% (prev 9.14%; Δ 1.12% > 0%) |
| Interest Coverage Ratio: -204.1 > 6 (EBITDA TTM -298.1m / Interest Expense TTM 1.47m) |
| A: 0.80 (Total Current Assets 623.8m - Total Current Liabilities 101.5m) / Total Assets 652.6m |
| B: -1.91 (Retained Earnings -1.25b / Total Assets 652.6m) |
| C: -0.43 (EBIT TTM -299.2m / Avg Total Assets 698.2m) |
| D: -2.29 (Book Value of Equity -1.25b / Total Liabilities 544.7m) |
| Altman-Z'' = -6.27 = D |
| DSRI: 0.27 (Receivables 13.6m/48.7m, Revenue 71.6m/68.0m) |
| GMI: 1.06 (GM 93.70% / 99.10%) |
| AQI: 1.76 (AQ_t 0.02 / AQ_t-1 0.01) |
| SGI: 1.05 (Revenue 71.6m / 68.0m) |
| TATA: -0.33 (NI -294.6m - CFO -78.0m) / TA 652.6m) |
| Beneish M = -3.43 (Cap -4..+1) = AA |
As of May 24, 2026, the stock is trading at USD 11.13 with a total of 5,228,325 shares traded.
Over the past week, the price has changed by +22.02%,
over one month by +18.05%,
over three months by +34.73% and
over the past year by +80.29%.
Kura Oncology has received a consensus analysts rating of 4.53. Therefore, it is recommended to buy KURA.
- StrongBuy: 10
- Buy: 3
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 31.2 | 180.1% |
P/B = 9.1586
Revenue TTM = 71.6m USD
EBIT TTM = -299.2m USD
EBITDA TTM = -298.1m USD
Long Term Debt = 9.75m USD (from longTermDebt, last quarter)
Short Term Debt = 1.28m USD (from shortTermDebt, last quarter)
Debt = 38.8m USD (from shortLongTermDebtTotal, last quarter) + Leases 14.5m
Net Debt = -93.4m USD (calculated: Debt 38.8m - CCE 132.2m)
Enterprise Value = 908.0m USD (1.00b + Debt 38.8m - CCE 132.2m)
Interest Coverage Ratio = -204.1 (Ebit TTM -299.2m / Interest Expense TTM 1.47m)
EV/FCF = -3.48x (Enterprise Value 908.0m / FCF TTM -260.9m)
FCF Yield = -28.74% (FCF TTM -260.9m / Enterprise Value 908.0m)
FCF Margin = -364.2% (FCF TTM -260.9m / Revenue TTM 71.6m)
Net Margin = -411.2% (Net Income TTM -294.6m / Revenue TTM 71.6m)
Gross Margin = 93.70% ((Revenue TTM 71.6m - Cost of Revenue TTM 4.51m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 1.39 (Enterprise Value 908.0m / Total Assets 652.6m)
Interest Expense / Debt = 3.78% (Interest Expense 1.47m / Debt 38.8m)
Taxrate = 21.0% (US default 21%)
NOPAT = -236.4m (EBIT -299.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.75 (Total Current Assets 623.8m / Total Current Liabilities 108.5m)
Debt / Equity = 0.36 (Debt 38.8m / totalStockholderEquity, last quarter 107.9m)
Debt / EBITDA = 0.31 (negative EBITDA) (Net Debt -93.4m / EBITDA -298.1m)
Debt / FCF = 0.36 (negative FCF - burning cash) (Net Debt -93.4m / FCF TTM -260.9m)
Total Stockholder Equity = 207.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -42.19% (Net Income -294.6m / Total Assets 652.6m)
RoE = -20.25% (Net Income TTM -294.6m / Total Stockholder Equity 1.45b)
RoCE = -20.43% (EBIT -299.2m / Capital Employed (Equity 1.45b + L.T.Debt 9.75m))
RoIC = -42.87% (negative operating profit) (NOPAT -236.4m / Invested Capital 551.4m)
WACC = 9.57% (E(1.00b)/V(1.04b) * Re(9.83%) + D(38.8m)/V(1.04b) * Rd(3.78%) * (1-Tc(0.21)))
Discount Rate = 9.83% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 6.23%
[DCF] Fair Price = unknown (Cash Flow -260.9m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.24 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: -0.43 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.91 | Chg30d=+4.23% | Revisions=+33% | Analysts=8
EPS next Quarter (2026-09-30): EPS=-0.93 | Chg30d=-3.21% | Revisions=+33% | Analysts=8
EPS current Year (2026-12-31): EPS=-3.52 | Chg30d=-5.21% | Revisions=+11% | GrowthEPS=-10.7% | GrowthRev=+40.4%
EPS next Year (2027-12-31): EPS=-2.55 | Chg30d=-4.68% | Revisions=+40% | GrowthEPS=+27.5% | GrowthRev=+126.2%
[Analyst] Revisions Ratio: +40%